Surveillance AFter Extremity Tumor surgerY

NCT03944798 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 310

Last updated 2024-11-22

No results posted yet for this study

Summary

Following treatment for a primary extremity sarcoma, patients remain at risk for the development of local and systemic disease recurrence. Metastasis (distant recurrence) to the lung is the most frequent single location of disease recurrence in sarcoma patients, occurring in almost half of all patients. Therefore, careful post-operative surveillance is an integral element of patient care. However, the detection of metastases does not necessarily affect long-term survival and may negatively impact quality of life. Surveillance strategies have not been well researched and have been identified as the top research priority in the extremity sarcoma field. Using a 2X2 factorial design to maximize efficiency and reduce overall trial costs, the SAFETY trial randomized 310 extremity soft-tissue sarcoma (STS) patients to determine the effect of surveillance strategy on overall patient survival after surgery for a STS of the extremity by comparing the effectiveness of both surveillance frequency (every 3 vs. every 6 months) and imaging modality (CT scans vs. chest radiographs).

Conditions

  • Soft Tissue Sarcoma
  • Lung Metastases

Interventions

OTHER

Frequency: Every 3 Months

every 3 months

OTHER

Frequency: Every 6 Months

every 6 months

OTHER

Imaging Modality: Chest Radiograph (CXR)

Chest radiograph (CXR)

OTHER

Imaging Modality: Chest CT

Chest computed tomography (CT)

Sponsors & Collaborators

  • Hamilton Academic Health Sciences Organization

    collaborator OTHER
  • Canadian Cancer Society (CCS)

    collaborator OTHER
  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV
  • American Academy of Orthopaedic Surgeons

    collaborator OTHER
  • Musculoskeletal Tumor Society

    collaborator UNKNOWN
  • McMaster University

    lead OTHER

Principal Investigators

  • Michelle Ghert, MD · McMaster University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-19
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • United States
  • Argentina
  • Australia
  • Austria
  • Belgium
  • Brazil
  • Canada
  • Germany
  • Italy
  • Malaysia
  • Netherlands
  • Portugal
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03944798 on ClinicalTrials.gov